Biogenysis, a subsidiary of Enzolytics, has partnered with Khalpey AI Lab in an effort to uncover biomarkers for early-onset Alzheimer’s disease. This debilitating illness affects people of all ages, making it imperative to identify and validate disease biomarkers for accurate diagnosis, prediction, and effective treatment. The emergence of high-throughput technology has resulted in vast amounts of biological data, which can be effectively managed and interpreted by AI in fields like microbiome research, genetics, and nutrition. The goal of this collaboration is not only to identify biomarkers for early-onset Alzheimer’s, but to discover new therapeutic targets that can slow down the progression of this devastating disease.
Dr. Zain Khalpey, the Director of the Khalpey AI Lab, stresses the significance of applied AI models in healthcare and asserts their commitment to advancements in this field. By integrating clinically applied artificial intelligence (AI) into patient care, they contribute to creating a brighter future for patients. Their innovative tools elevate patient data collection and analysis to unparalleled heights, enabling healthcare professionals to make better-informed medical decisions. This technology even allows them to predict and prevent adverse patient events before they occur. With the Biogenysis partnership, Khalpey AI Lab’s tools are significantly enhanced, and that should lead to improved clinical outcomes.
Dr. Gaurav Chandra, the CEO of Biogenysis, highlights the company’s dedicated approach to advancing drug discovery through AI. Their AI platform aspires to transform healthcare from a reactive approach to a proactive one, enabling predictive, preventive, personalized, and participatory care. Through their collaboration with Khalpey AI Lab, their aim is to identify early biomarkers for Alzheimer’s disease and uncover new therapeutic targets to slow down its progression. This AI model integrates the fields of genetics, nutrition, and microbiome and can also be applied to other chronic diseases. The partnership with Dr. Zain Khalpey’s AI Lab promises to expedite their progress in providing effective medical care.
The partnership between Biogenysis and Khalpey AI Lab embodies the commitment of both entities to advancing healthcare through innovative AI models and cutting-edge research. By harnessing the power of artificial intelligence, they aim to revolutionize the field of medical care, improve patient outcomes, and make significant rapid strides in the fight against Alzheimer’s and other infectious diseases.
The whytry.ai article you just read is a brief synopsis; the original article can be found here: Read the Full Article…
